Improving Hepatitis B and C Care Cascades; Focus on Increased Testing and Diagnosis - Supplement

(CDC-RFA-PS17-17020301SUPP19)

Funded Partners:
California, District of Columbia, Louisiana, Michigan, New York City, Oregon, Rhode Island, South Carolina, West Virginia

Award Period:
1 year (September 2019 – August 2020)

 Total Amount of Award:
$3.5 million (average award of $450,000 per jurisdiction)

 Overarching objectives of the program:
The opioid crisis, involving the misuse of prescription opioid pain relievers as well as heroin and fentanyl usage, has resulted in accompanying increases in injection drug use in many jurisdictions across the nation.  This has caused an increase in overdose deaths and viral hepatitis infections annually and is threatening recent progress made in HIV prevention, especially among young adults.

Through this funding opportunity, CDC aims to address infectious disease consequences of the opioid crisis by facilitating the work of state and local health departments to offer testing and linkage to care where people who inject drugs are accessible.

Objectives for funded partners:
Through this cooperative agreement, state and local health departments are:

  • collaborating with partner organizations that are within designated high-burden areas to conduct hepatitis B and hepatitis C testing and linkage to care in high-impact settings, (e.g., syringe services programs, substance abuse treatment facilities, emergency departments, correctional facilities); and
  • increasing the number of persons that are tested for hepatitis B and hepatitis C and are made aware of their infection status.

NOFO Announcement:
https://www.grants.gov/web/grants/view-opportunity.html?oppId=314079external icon